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Objectives The objective of this study was to evaluate whether the regressive effects of aggressive lipid-lowering therapy
with atorvastatin on coronary plaque volume (PV) in patients with acute coronary syndrome (ACS) are general-
ized for other statins in multicenter setting.
Background A previous single-center study reported beneficial regressive effects of atorvastatin in patients with ACS on PV of
the nonculprit site by intravascular ultrasound (IVUS) evaluation. The effect of statins other than atorvastatin on
PV has not been evaluated in the setting of ACS.
Methods The JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome) study was a
prospective, randomized, open-label, parallel group study with blind end point evaluation conducted at 33 cen-
ters in Japan. A total of 307 patients with ACS undergoing IVUS-guided percutaneous coronary intervention were
randomized, and 252 patients had evaluable IVUS examinations at baseline and 8 to 12 months’ follow-up. Pa-
tients were randomly assigned to receive either 4 mg/day of pitavastatin or 20 mg/day of atorvastatin. The pri-
mary end point was the percentage change in nonculprit coronary PV.
Results The mean percentage change in PV was 16.9  13.9% and 18.1  14.2% (p  0.5) in the pitavastatin and
atorvastatin groups, respectively, which was associated with negative vessel remodeling. The upper limit of 95%
confidence interval of the mean difference in percentage change in PV between the 2 groups (1.11%, 95% confi-
dence interval: 2.27 to 4.48) did not exceed the pre-defined noninferiority margin of 5%.
Conclusions The administration of pitavastatin or atorvastatin in patients with ACS equivalently resulted in significant regression of
coronary PV (Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome; NCT00242944).
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The JAPAN-ACS Study July 21, 2009:293–302Many large-scale pivotal clinical
trials (1–3) have shown that
3-hydroxy-3-methyl-glutaryl co-
enzyme A reductase inhibitors
(statins) reduce both atherogenic
lipoproteins as well as cardiovas-
cular morbidity and mortality. In
addition, several previous multi-
center studies in which the au-
thors used intravascular ultra-
sound (IVUS) imaging revealed
that statins attenuate the pro-
gression of atherosclerosis or
even diminish plaque volume
(4,5). An IVUS study in patients
with acute coronary syndrome
(ACS) demonstrated that statin
therapy with 20 mg/day of ator-
vastatin could reduce nonculprit
oronary plaque volume (6). However, this study was a
elatively small trial conducted at a single center. This
bservation, if confirmed in a larger multicenter study, could
ddress one of the mechanisms of improvement of clinical
utcome provided by administration of statins in patients
ith ACS (7–10).
The effect of statins other than atorvastatin on plaque
olume (PV) has not been evaluated in the setting of ACS.
itavastatin is a statin that is commonly used in Japan,
outh Korea, and Thailand. It has been demonstrated that
ts ability to lower levels of low-density lipoprotein choles-
erol (LDL-C) is comparable with that of atorvastatin (11).
herefore, a multicenter study using a central IVUS core
aboratory was designed to assess the effect of pitavastatin on
oronary PV compared with that of atorvastatin in patients
ith ACS.
ethods
tudy design and ethical considerations. The JAPAN-
CS (Japan Assessment of Pitavastatin and Atorvastatin in
cute Coronary Syndrome) study was a prospective, ran-
omized, open-label, parallel group study with blind end-
oint evaluation at 33 centers to examine the effect of 8 to
2 months’ treatment with pitavastatin versus atrovastatin in
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n advisory member of Kowa Pharmaceutical and has received honoraria for the
ectures from Kowa Pharmaceutical and Astellas Pharma. Dr. Saito has received
onoraria for lectures from Kowa Pharmaceutical. Dr. Daida is an advisory member
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rom Kowa Pharmaceutical, Pfizer, and Astellas Pharma. Dr. Matsuzaki is an advisory
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and Acronyms
ACS  acute coronary
syndrome
CRP  C-reactive protein
EEM  external elastic
membrane
FAS  full analysis set
HDL-C  high-density
lipoprotein cholesterol
IVUS  intravascular
ultrasound
LDL-C  low-density
lipoprotein cholesterol
PCI  percutaneous
coronary intervention
PV  plaque volumeN
Manuscript received December 2, 2008; revised manuscript received March 23,
009; accepted April 2, 2009.oronary plaque regression in nonpercutaneous coronary
ntervention (PCI) sites of the culprit vessel in patients with
CS. A documentation of the present study design was
ublished before the dataset was locked (12). This study was
onducted according to the Declaration of Helsinki and
ith the approval of the institutional review boards of all 33
articipating institutions. Written informed consent to
articipate was obtained from all of the patients enrolled.
atient enrollment and randomization. Patients with
CS who satisfied all criteria for inclusion were selected
fter having a successful PCI under IVUS guidance. We
efined ACS as unstable angina pectoris, non–ST-segment
levation myocardial infarction (MI) or ST-segment eleva-
ion MI. These diagnoses were made if patients met at least
of the following 3 conditions: 1) ischemic ECG changes;
) the increase (2 times) in serum creatine kinase or
reatine kinase, myocardial band, or a positive troponin T
esult; and 3) the presence of symptoms suggestive of ACS.
standard antiplatelet therapy and other medications for
CS were provided.
The patients were randomized within 72 h after PCI to
eceive either pitavastatin (4 mg) or atorvastatin (20 mg)
aily. The dose of 20 mg/day of atorvastatin was selected
ecause when such doses were used in the ESTABLISH
Demonstration of the Beneficial Effect on Atherosclerotic
esions by Serial Volumetric Intravascular Ultrasound
nalysis During Half a Year After Coronary Event) study
hey significantly reduced coronary PV in patients with
CS (6) and because this dose was the most intensive
ermitted one to reduce LDL-C in Japan at the beginning
f this trial. In addition, the pitavastatin dosage of 4 mg/day
as selected because it causes a similar LDL-C–lowering
ffect to 20 mg/day of atorvastatin (11). We did not include
control group of patients not receiving statin treatment
ecause of ethical reasons. The randomization was stratified
y the presence of diabetes mellitus, sex, and total choles-
erol level by use of a web response system, which generated
ssociation sequence. The IVUS examination was per-
ormed at baseline and repeated after 8 to 12 months’
dministration of the allocated drugs.
Blood examinations for lipid levels and inflammatory
arkers were performed at baseline and follow-up at 8 to 12
onths. Lipid profiles and other biomarkers were measured
t SRL Co., Ltd., Tokyo, Japan, and pentraxin3 at Perseus
roteomics Inc., Tokyo, Japan. Safety was evaluated by
egular medical examination and laboratory tests at 1, 3, and
to 12 months after enrollment. The independent event
ssessment committee evaluated major adverse cardiac
vents and any other adverse events.
xamination with IVUS. After IVUS-guided PCI of the
ulprit lesion of ACS, IVUS examination was performed in
oth the longest and least angulated culprit vessel segment
eeting inclusion criteria. After 200 g of intracoronary
itroglycerin was administered, a 40-MHz, 2.6-F (0.87-
m) IVUS catheter (Atlantis SR Pro2, Boston Scientific,
atick, Massachusetts) was advanced into the culprit vessel,
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July 21, 2009:293–302 The JAPAN-ACS Studynd the transducer was positioned as far distally as could be
afely reached. This procedure was designed to select the
ongest-possible vessel segment for analysis. A motorized
ullback device withdrew the transducer at a speed of 0.5
m/s. The consoles used were ClearView or Galaxy 2
ystems (Boston Scientific). The same imaging system with
he same type of IVUS catheter was used for both the
aseline and the follow-up examinations When the angular
pan of the acoustic shadow of calcification or attenuation
y some noncalcified tissues was 90°, the case was ex-
luded. After an 8- to 12-month treatment period, IVUS
xaminations were performed under the conditions identical
o the baseline.
ore laboratory analysis of IVUS. Two independent ex-
erienced investigators who were unaware of the patient
roup allocation performed the quantitative IVUS analysis
t the central core laboratory. Baseline and follow-up IVUS
mages were reviewed together on a display, and target
egments were selected. The target segment was determined
t a non-PCI site (5 mm proximal or distal to the PCI
ite) of culprit vessel with a reproducible index, usually a
ranch site, on the PCI vessel. Spotty calcification, side
ein, and distances from side branch, orifice, left anterior
escending-left circumflex branch bifurcation, and stent
dge also were referred. Subsequently, every 6th image (0.1
m apart) was manually traced on a commercially available
VUS measurement software (echoPlaque2, INDEC sys-
ems Inc., Santa Clara, California). Moreover, this software
utomatically interpolated the tracing of 5 cross sections in
etween the 2 manually traced images. Therefore, the
olume was calculated from each of 0.017-mm spaced
egments. The final cross section for measurement was
btained at a proximal fiduciary site.
The IVUS measurements were performed according
o the standards of the American College of Cardiology and
he European Society of Cardiology (13). These measure-
ents are present in the standard manner, for which
ccuracy and reproducibility have been well established (14).
he primary end point was the percent change in coronary
V during the observation period:
PV follow-up baseline
PV baseline
 100
oronary PV was calculated as the sum of the differences
etween the external elastic membrane (EEM) and lumen
rea across all evaluated frames as: PV  (EEMCSA
UMENCSA), where EEMCSA  external elastic mem-
rane cross-sectional area and LUMENCSA  luminal
ross-sectional area.
Major secondary end points include nominal change in
ercent PV (%PV) and nominal change in normalized plaque
olume (NPV) (follow-up minus baseline, respectively): sNPVPV
LMED
LMEASURED
here LMED  median value of observed length in all
ubjects and LMEASURED observed length of each plaque.
tatistical analysis. A detailed structure of statistical anal-
ses in the current study was described elsewhere (12). In
rief, this study aims to evaluate whether the effect of
itavastatin on coronary PV would not be inferior to that of
torvastatin and vice versa. Two-sided noninferiority was
valuated by analysis of variance with adjustment for sex, the
resence of diabetes mellitus, and total cholesterol level on
dmission as previously described (12). We decided nonin-
eriority margin as follows: 1) in the ESTABLISH study,
he % change in PV of atorvastatin was 13.1  12.8%; 2)
tandard deviation (12.8) multiplied by 0.36 (15) yielded
.608, rounded to 5; and 3) the noninferiority margin was
ecided as 5%. We calculated 150 subjects in each group
ith an alpha level of 5%, a power of 80%, and a dropout
ate of 30%.
We used full analysis set (FAS) of data for primary
nalyses. Data of patients were included in FAS if patients
ad ACS and measurable IVUS both at the enrollment and
t follow-up. We prepared per-protocol analysis set of data
f enrolled patients completely met the inclusion and exclu-
ion criteria and followed the protocol as it was. If patients
eceived the study drug at least once, they were included in
he safety analysis set of data.
After the descriptive statistics, comparisons of continuous
ariables between the 2 groups were performed by the
-sample t test or Wilcoxon rank sum test, and those
etween the baseline and the follow-up by 1-sample t tests
r Wilcoxon sign rank test according to their distributions.
omparisons of categorical values between the 2 groups
ere performed by chi-square tests and Fisher exact tests.
e used general linear models to assess relationships
etween the percent change in coronary PV and several
actors, including serum lipid profile at 8 to 12 months, or
o assess interobserver and intraobserver variabilities for
easuring plaque area. The numbers of adverse events were
ssessed to determine safety profiles. The significance level
as 5% 2-sided (2.5% 1-sided), and all statistical analyses
ere performed by the use of the SAS system version 9.1
SAS Institute, Cary, North Carolina).
esults
atient population. The grouping of patients in the
resent study is shown in Figure 1. Between November 1,
005, and October 31, 2006, 307 patients were enrolled at
3 centers in Japan, and 153 patients were randomly
ssigned to receive pitavastatin and 154 to atorvastatin. The
VUS images qualified for evaluation both at baseline and at
ollow-up were obtained in 125 patients (82%) in the
itavastatin group and in 127 patients (82%) in the atorva-
tatin group. The median follow-up time with intraquartile
r
m
s
g
E
p
S
u
t
L
f
t
m
f
2
a
l
s
i
p
i
g
E
I
i
p
c
0
t

P
(
i
p
v
p
d

t
296 Hiro et al JACC Vol. 54, No. 4, 2009
The JAPAN-ACS Study July 21, 2009:293–302ange in the pitavastatin group was 9.3 (range 8.5 to 10.3)
onths and 9.6 (range 8.6 to 10.5) months in the atorva-
tatin group, respectively.
There was no significant difference in baseline demo-
raphics and characteristics between the 2 groups (Table 1).
ighty-two percent of patients were men, and 29% of total
atients had diabetes. Sixty-four percent of patients had
T-segment elevation MI, and drug-eluting stents were
sed in 32% and bare-metal stents in 66%. Plaques proximal
o the PCI sites were analyzed in 70% of patients.
aboratory results. We found that LDL-C decreased
rom 130.9  33.3 mg/dl (3.39  0.86 mmol/l) at baseline
o 81.1  23.4 mg/dl (2.10  0.61 mmol/l) at 8 to 12
onths’ follow-up (p 0.001) in the pitavastatin group and
rom 133.8  31.4 mg/dl (3.47  0.81 mmol/l) to 84.1 
7.4 mg/dl (2.18  0.71 mmol/l; p  0.001) in the
torvastatin group (Table 2). We found that high-density
ipoprotein cholesterol (HDL-C) as well as triglycerides
howed comparable increase between the 2 groups. The
nflammatory markers, high-sensitivity C-reactive protein,
Figure 1 Disposition of Patients
FAS  full analysis set; IVUS  intravascular ultrasound; PCI  percutaneous corentraxin3, and white blood cell counts were markedly [ncreased at baseline and were not different between the 2
roups in terms of percent change.
fficacy analysis with IVUS. We randomly selected 93
VUS cross-sectional images from 31 patients to assess the
ntraobserver and interobserver variabilities for measuring
laque area by 2 independent technicians. The correlation
oefficient and mean difference  SD were 0.99 and 0.02 
.24 mm2 (of the absolute mean value, 6.97 4.33 mm2, of
he samples) for intraobserver variability and 0.98 and 0.13
0.32 mm2 for interobserver variability.
As a primary end point, the percent change in coronary
V showed a significant regression for both groups
16.9  13.9% in the pitavastatin group, 18.1  14.2%
n the atorvastatin group, and 17.5  14.0% for total
atients) (Table 3). Noninferiority of pitavastatin to ator-
astatin and also atorvastatin to pitavastatin in terms of
ercent change in PV was proved (Fig. 2). The mean
ifference of drug effects on percent change in PV (p –
a), adjusted for sex, the presence of diabetes mellitus, and
otal cholesterol level, was 1.11% (95% confidence interval
ntervention; PPS  per protocol set; SAS  safety analysis set.onary iCI]: 2.27% to 4.48%). The upper limit of 95% CI of this
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July 21, 2009:293–302 The JAPAN-ACS Studyifference did not exceed the pre-defined noninferiority
argin of 5%. The direction of difference in per-protocol
aseline Patientharacteristics and Concomitant DrugsTable 1 Baseline PatientCharacteristics and Concomitant Drugs
Characteristic
Pitavastatin
(n  125)
Atorvastatin
(n  127)
Age (yrs) 62.5 11.5 62.4 10.6
Male 103 (82.4) 103 (81.1)
BMI (kg/m2) 24.5 3.7 24.2 3.3
Waist circumference (cm) 87.2 9.5 87.0 8.6
Diabetes 36 (28.8) 38 (29.9)
Hypertension 73 (58.4) 84 (66.1)
Family history of CAD 24 (19.2) 21 (16.5)
Smoking 57 (45.6) 62 (48.8)
Alcohol drinker 59 (47.2) 62 (48.8)
Type of ACS
STEMI 75 (60.0) 87 (68.5)
NSTEMI 18 (14.4) 18 (14.2)
UAP 32 (25.6) 22 (17.3)
Abnormal O-wave 46 (36.8) 40 (31.5)
Max CK (IU/l), median (IQR) 1,173 (206–2,664) 1,400 (349–2,806)
Culprit vessel
RCA 33 (26.4) 48 (37.8)
LAD 75 (60.0) 61 (48.0)
LCx 16 (12.8) 18 (14.2)
LMT 1 (0.8) 0
Analysis segment
Proximal to the treated site 86 (68.8) 90 (70.9)
Disital to the treated site 39 (31.2) 37 (29.1)
BMS 77 (61.6) 89 (70.1)
DES 45 (36.0) 35 (27.6)
Other than stent (POBA) 3 (2.4) 3 (2.4)
Concomitant drugs
Aspirin 124 (99.2) 124 (97.6)
Ticlopidine 102 (81.6) 107 (84.3)
Clopidogrel 9 (7.2) 8 (6.3)
Beta-blocker 55 (44.0) 61 (48.0)
ACE inhibitor 35 (28.0) 39 (30.7)
ARB 57 (45.6) 68 (53.5)
PPAR- agonist 4 (3.2) 6 (4.7)
Sulfonylurea 12 (9.6) 8 (6.3)
-Gl 10 (8.0) 11 (8.7)
Calcium blocker 25 (20.0) 24 (18.9)
Nitrate 21 (16.8) 17 (13.4)
Diuretic 10 (8.0) 9 (7.1)
Aldosterone blocker 3 (2.4) 2 (1.6)
Digitalis 3 (2.4) 2 (1.6)
Other antiplatelet agents 10 (8.0) 7 (5.5)
Warfarin 5 (4.0) 2 (1.6)
Antiarrhythmic agent 1 (0.8) 1 (0.8)
ata are expressed as n (%) unless otherwise specified. Continuous variables were represented by
ean  SD or median (IQR). There were no significant differences of any characteristics between
he 2 groups.
ACE  angiotensin-converting enzyme; ACS  acute coronary syndrome; ARB  angiotensin
eceptor blocker; -GI  alpha-glucosidase inhibitor; BMI  body mass index; BMS  bare-metal
tent; CAD  coronary artery disease; CK  creatine kinase; DES  drug-eluting stent; IQR 
ntraquartile range; LAD left anterior descending; LCx left circumflex branch; LMT left main
runk; NSTEMI  non–ST-elevation myocardial infarction; POBA  plain old balloon angioplasty;
CA  right coronary artery; STEMI  ST-elevation myocardial infarction; UAP  unstable angina
ectoris.nalysis set setting, mean value of 1.36% (95% CI: 2.15% co 4.88%), was consistent with FAS setting. Secondary
fficacy end points such as %PV and normalized PV were
ignificantly reduced in both groups (Table 3).
These benefits were associated with significant negative
essel remodeling in both groups (113.0  59.3 mm3 to
05.4 55.0 mm3), which consequently provided slight but
ignificant lumen enlargement (56.1  59.3 mm3 to 57.8 
0.5 mm3). Reduction in EEM volume correlated with the
ecreased PV (r  0.7), but there was no correlation
etween change in lumen volume and change in PV (Fig. 3).
igure 4 showed representative examples of IVUS in a
ingle patient with ACS at the baseline and the follow-up
eriod in pitavastatin group.
laque regression and biomarkers. Because there was no
ignificant difference in percent change in PV between the 2
roups, the correlation between LDL-C level and percent
hange in PV was evaluated in the whole FAS patients.
here were no significant correlations between LDL-C
evel at follow-up or at baseline and percent change in PV.
ercent change in LDL-C level during the study period also
id not significant correlate with percent change in PV (Fig. 5).
n addition, there were no significant correlations between
igh-sensitivity C-reactive protein level at follow-up or at
aseline and percent change in PV.
dverse events. There were no significant differences in
he prevalence of these major adverse cardiac events and
dverse events between the pitavastatin group and the
torvastatin group (Table 4). The study drugs were discon-
inued because of either adverse reactions or abnormality of
aboratory value only in 2.7% and 4.7% of the pitavastatin
roup and the atorvastatin group, respectively.
iscussion
ur study demonstrated that aggressive lipid-lowering ther-
py with either pitavastatin 4 mg/day or atorvastatin 20
g/day achieved significant regression of the coronary PV
ith negative vessel remodeling in patients with ACS based
n a randomized, large-scale, multicenter, central IVUS
ore laboratory evaluation study. Therefore, the results
rovided support to the hypothesis that administration of
tatins after the onset of ACS has the potential to reverse
he process of atherosclerosis, thereby improving clinical
utcome (7–10). Moreover, the results showed that pitavas-
atin as well as atorvastatin provided a comparable benefit to
educe PV in such patients. This observation also general-
zed the effect of statins other than atorvastatin on PV in the
etting of ACS.
The degree of percent change in PV was 17.5% for total
atients in this study. This beneficial regressive effect was
imilar to that reported by the ESTABLISH single-center
tudy (13.1%) (6), even more than that of the REVERSAL
rial (0.4%, median in the atorvastatin group) that used a
imilar primary end point. One of the potential reasons for this
ight be the difference in clinical presentation (ACS vs. stableoronary artery disease). Evidence has accumulated that shows
Laboratory ResultsTable 2 Laboratory Results
Baseline Follow-Up
Percent Change (%)
Pitavastatin
(n  125)
Atorvastatin
(n  127)
Pitavastatin
(n  125)
Atorvastatin
(n  127)
Pitavastatin
(n  125)
p Value
Compared
With Baseline
Atorvastatin
(n  127)
p Value
Compared
With Baseline
p Value
Between
Groups
TC 196.5 35.6 197.9 36.4 151.3 28.0 152.8 33.1 21.6 16.0 0.001 21.9 17.7 0.001 0.9
LDL-C 130.9 33.3 133.8 31.4 81.1 23.4 84.1 27.4 36.2 19.5 0.001 35.8 22.9 0.001 0.9
TG 119.2 53.2 116.7 58.1 126.8 80.3 120.7 59.1 16.2 59.9 0.003 21.2 75.5 0.002 0.6
HDL-C 45.0 10.1 43.9 9.4 48.8 12.7 47.1 11.7 9.9 23.5 0.001 8.0 21.4 0.001 0.5
HDL-C baseline 40 mg/dl 34.6 3.4 34.5 4.0 41.4 7.2 37.8 7.5 20.6 24.6 (n 39) 0.001 10.8 25.4 (n 46) 0.006 0.08
HDL2-C 30.4 10.0 29.5 8.6 33.0 12.3 31.7 10.5 10.8 31.4 0.001 8.7 28.0 0.001 0.6
HDL3-C 18.5 3.6 18.0 3.8 17.9 3.2 17.4 3.5 0.5 21.9 0.8 1.4 21.5 0.5 0.7
RLP-C 4.5 2.7 4.2 2.4 4.1 3.6 3.7 2.5 4.7 87.9 0.6 6.2 80.9 0.4 0.9
Small dense LDL (RM value) 0.35 0.04 0.36 0.05 0.34 0.04 0.34 0.03 2.6 11.1 0.01 3.4 11.9 0.002 0.6
Non–HDL-C 151.1 33.1 153.5 33.7 102.6 25.2 105.7 32.2 30.5 18.9 0.001 30.1 20.8 0.001 0.9
LDL-C/HDL-C 3.0 0.9 3.2 0.9 1.8 0.6 1.9 0.7 40.3 19.4 0.001 38.8 23.1 0.001 0.6
ApoA-I 111.8 19.8 109.8 19.2 130.9 24.8 124.5 24.1 18.5 21.6 0.001 14.0 19.4 0.001 0.1
ApoB 103.6 23.3 104.8 23.2 73.3 17.0 74.6 21.3 27.6 18.3 0.001 27.6 20.2 0.001 0.99
ApoE 4.1 1.2 4.2 1.1 3.6 1.0 3.5 1.0 9.4 23.5 0.001 12.7 23.5 0.001 0.3
ApoB/ApoA-I 0.95 0.25 0.97 0.24 0.58 0.16 0.62 0.22 37.7 16.1 0.001 35.7 18.2 0.001 0.4
MDA-LDL (U/l) 130.2 43.6 128.9 49.1 88.1 27.4 93.9 34.6 28.4 25.3 0.001 22.1 28.2 0.001 0.1
Phospholipid 200.4 30.8 199.0 33.1 183.7 31.1 177.4 29.8 7.4 15.8 0.001 10.1 14.4 0.001 0.2
Lp(a) 20.2 16.7 22.9 21.9 22.7 22.0 24.2 25.8 5.9 45.6 0.2 9.8 54.9 0.049 0.5
hs-CRP (mg/l), median (IQR) 19.9 (7.1–71.1) 14.9 (4.7–62.4) 0.54 (0.36–1.1) 0.53 (0.26–1.2) 97.3 (99.1 to89.6) 0.001* 95.4 (99.0 to84.5) 0.001* 0.4†
PTX3 (ng/ml), median (IQR) 5.9 (3.8–8.9) 5.6 (3.8–9.0) 2.1 (1.5–2.8) 1.9 (1.3–2.6) 64.3 (77.5 to45.1) 0.001* 68.9 (79.1 to52.4) 0.001* 0.9†
WBC (cells/l), median (IQR) 8,820 (7,015–11,400) 9,300 (7,580–11,200) 6,000 (5,300–7,200) 6,000 (5,005–7,268) 31.6 (44.9 to16.6) 0.001* 33.6 (45.1 to17.2) 0.001* 0.7†
HbA1c (%) 5.9 1.3 6.0 1.1 5.9 1.1 5.9 0.89 0.6 10.5 0.5 0.6 10.5 0.5 0.98
Values are mg/dl unless otherwise indicated. Continuous variables were represented by mean  SD or median (IQR). The last column indicates the comparison of percent change in valuables between pitavastatin and atorvastatin group. SI conversions: To convert total
cholesterol, LDL-C, HDL-C, HDL2-C, HDL3-C, remnant lipoprotein-C (RLP-C), non–HDL-C to mmol/l, multiply by 0.0259; apolipoprotein (apo)A-I, apoB, apoE to g/l, multiply by 10; malonyl-dialdehyde (MDA)-low-density lipoprotein (LDL), phospholipid and lipoprotein (a) [Lp(a)]
to mg/l, multiply by 10; PTX3 to g/l, multiply values by 1. *Wilcoxon sign rank test. †Wilcoxon rank sum test.
CRP  C-reactive protein; Hb  hemoglobin; HDL-C  high-density lipoprotein cholesterol; hs-CRP  high-sensitivity C-reactive protein; IQR  intraquartile range; IVUS  intravascular ultrasound; LDL-C  low-density lipoprotein cholesterol; PCI  percutaneous coronary
intervention; PTX3  pentraxin 3; RM  relative migration; TC  total cholesterol; WBC  white blood cell counts.
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July 21, 2009:293–302 The JAPAN-ACS Studyatients with ACS have many greater-risk nonculprit plaques
16–19). The plaques in the most-diseased 10-mm segments
howed more regression than whole coronary artery in the
EVERSAL trials (4), and the %PV at the baseline in this
tudy was relatively large compared with those in both trials
VUS ResultsTable 3 IVUS Results
Baseline
Both Groups
(n  252)
Pitavastatin
(n  125)
Atorva
(n 
Plaque volume (mm3) 56.9 32.2 49.8 28.8 63.9
Percent plaque volume (%) 50.0 10.3 49.4 10.8 50.5
Normalized plaque volume (mm3) 54.6 18.9 52.7 19.4 56.4
Vessel volume (mm3) 113.0 59.3 100.2 54.2 125.6
Lumen volume (mm3) 56.1 31.5 50.5 29.7 61.6
IVUS lesion length (mm) 6.7 3.0 6.1 2.8 7.3
Both Groups
(n  252)
p Value
Compared
With Baseline
P
(
Plaque volume (mm3) 9.4 9.8 0.001 
Percent plaque volume (%) 6.0 6.2 0.001 
Normalized plaque volume (mm3) 9.3 8.4 0.001 
Vessel volume (mm3) 7.7 14.9 0.001 
Lumen volume (mm3) 1.8 10.6 0.0093
IVUS lesion length (mm) S/B —
Both Groups
(n  252)
p Value
Compared
With Baseline
P
(
Plaque volume (mm3) 17.5 14.0 0.001 1
Percent plaque volume (%) NA 0.001
Normalized plaque volume (mm3) NA 0.001
Vessel volume (mm3) 6.0 11.4 0.001 
Lumen volume (mm3) 6.5 20.4 0.001
IVUS lesion length (mm) S/B —
ontinuous variables were represented by mean  SD.
IVUS  intravascular ultrasound; NA  not applicable; S/B  same as the baseline.
Figure 2 Primary End Point (Noninferiority Test)
The difference of drug effects on percent change in plaque volume (p – a) adjus
represents percent change in plaque volume of the pitavastatin group and a repr
evident for this end point.JAPAN-ACS, 50%; REVERSAL, 40%). Furthermore,
here was relatively greater proportion of the patients who were
dministered statins de novo after the entry of this trial. It is
lso possible there are genetic, racial, or ethnic differences in
erms of response to statins.
Follow-Up
p Value
Between
Groups
Both Groups
(n  252)
Pitavastatin
(n  125)
Atorvastatin
(n  127)
p Value
Between
Groups
0.001 47.5 29.1 41.6 25.0 53.3 31.7 0.0013
0.4 44.0 10.8 43.7 11.0 44.3 10.7 0.7
0.1 45.3 18.0 43.9 17.7 46.6 18.3 0.2
0.001 105.4 55.0 93.3 48.7 117.2 58.3 0.001
0.0046 57.8 30.5 51.7 27.9 63.9 31.7 0.0013
0.0021 S/B S/B S/B —
Nominal Change
tatin
25)
p Value
Compared
With Baseline
Atorvastatin
(n  127)
p Value
Compared
With Baseline
p Value
Between
Groups
8.9 0.001 10.6 10.6 0.001 0.05
6.3 0.001 6.3 6.1 0.001 0.5
8.2 0.001 9.8 8.6 0.001 0.3
15.2 0.001 8.3 14.7 0.001 0.5
10.5 0.2 2.3 10.5 0.019 0.4
— — — —
Percent Change (%)
tatin
25)
p Value
Compared
With Baseline
Atorvastatin
(n  127)
p Value
Compared
With Baseline
p Value
Between
Groups
13.9 0.001 18.1 14.2 0.001 0.5
0.001 NA 0.001 0.5
0.001 NA 0.001 0.3
11.8 0.001 6.2 11.1 0.001 0.8
21.5 0.0012 6.6 19.4 0.001 0.9
— — — —
r sex, the presence of diabetes mellitus, and total cholesterol level, where p
that of the atorvastatin group. Noninferiority of pitavastatin to atorvastatin wasstatin
127)
 33.9
 9.7
 18.3
 61.5
 32.3
 3.1
itavas
n  1
8.2
5.7
8.7
7.0
1.2
—
itavas
n  1
6.9
NA
NA
5.9
6.4
—ted fo
esents
t
a
5
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The JAPAN-ACS Study July 21, 2009:293–302The correlation between the reduction of LDL-C and
he regression of PV was not significant in the present study
s compared with previous placebo-controlled studies (Fig.
) (6,20). One of the reasons might be that this study did
Figure 3 Correlation Between the Change in Plaque Volume an
There were significant correlations between the change in plaque volume and the
tion was observed between the change in plaque volume and the change in lumen
remodeling.
ID # 008
64y.o. male
Pitavastatin
Baseline (mm3)
Plaque Volume=84.6
Vessel Volume=168.8
Lumen Volume=84.2
Follow Up (mm3)
Plaque Volume=71.8
Vessel Volume=163.7
Lumen Volume=91.8
Percent Change
Plaque Volume=-15.1%
Vessel Volume=-3.0%
Lumen Volume=+9.0%
A
C
Figure 4 Representative Cases of IVUS Analysis
Shown are intravascular ultrasound (IVUS) images of the same cross section at th
leading edges of lumen and external elastic membrane. There is substantial reducot have a placebo arm of patients not receiving lipid-
owering therapy, which was not included for ethical rea-
ons. Regression in PV was observed in a broad spectrum of
atients regardless of the baseline LDL-C level. Pleiotropic
Change in Lumen Volume and EEM Volume
in external elastic membrane (EEM) volume (A), whereas no significant correla-
e (B). The regression of plaque volume was associated with negative vessel
B
D
line (A) and at the follow-up (B). C and D correspond to A and B with outlined
plaque area observed for the cross-sectional images.d the
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July 21, 2009:293–302 The JAPAN-ACS Studyffects unrelated to LDL-C reduction might be one of the
echanisms of plaque regression. Other pharmacologic and
ifestyle interventions applied after the onset of ACS might
ontribute to the modification of the plaque. In addition,
V regression observed in our study was associated with
egative vessel remodeling, which might suggest that non-
ulprit plaques in patients with ACS were stabilized by
tatins (21).
tudy limitations. The observation of a single plaque in
he culprit vessel may not represent the pan-coronary
ature of a plaque. Meanwhile, it has been documented
hat the ACS may represent the pan-coronary process of
ulnerable plaque development, suggesting that a single
laque can reflect the general feature of whole coronary
rtery (19). Another criticism may be that arteries un-
ergoing mechanical interventions were included, which
ould have affected atheroma measurements. However,
VUS examination for nonculprit vessel in emergent
atients with ACS was not possible because of ethical
easons. IVUS might not be appropriate to identify
hrombosis. It has been reported that thrombosis can be
dentified by IVUS with a sensitivity of 50% (22).
owever, fresh thrombus, which is frequently seen in
CS, can be detected with a true-positive rate of 80%
23). Therefore, meticulous care was taken to exclude
hrombus in the present study as strictly as possible with
riteria that thrombus in an IVUS image is usually mobile
ACE and Adverse EventsTable 4 MACE and Adverse Events
Pitavastatin
(n  147)
Atorvastatin
(n  149) p Value
MACE 30 (20.4) 34 (22.8) 0.6
Myocardial Infarction 0 3 (2.0) 0.2‡
Coronary revascularization 30 (20.4) 31 (20.8) 0.9
TLR 16 (10.9) 19 (12.8) 0.6
TVR 9 (6.1) 8 (5.4) 0.8
Other vessel revascularization 8 (5.4) 9 (6.0) 0.8
Death from any cause 0 0 —
Adverse drug reaction 3 (2.0) 3 (2.0) 0.99
Myalgia 0 1 (0.7) 0.99‡
Eczema 2 (1.4) 3 (2.0) 0.99‡
Depression 1 (0.7) 0 0.5‡
Vomiting 1 (0.7) 0 0.5‡
Abnormality of laboratory value 19 (12.9) 17 (11.4) 0.7
AST/ALT* 11 (7.5) 11 (7.4) 0.97
CK† 8 (5.4) 8 (5.4) 0.98
Discontinuation 4 (2.7) 7 (4.7) 0.4
Adverse drug reaction 1 (0.7) 2 (1.3) 0.99‡
Abnormality of laboratory value 3 (2.0) 5 (3.4) 0.7‡
100% adherence 118 (80.3) 110 (73.8) 0.2
ata are expressed as n (%) unless otherwise specified. The chi-square test was used unless
therwise specified. *Upper than 100 (IU/l); in these, causes independent from trial drugs were
uspected in 3 cases of the pitavastatin group and 3 of the atorvastatin group respectively. †Upper
han 350 (IU/l); in these, causes independent from trial drugs were suspected in 1 cases of the
itavastatin group and 1 of the atorvastatin group respectively. ‡Fisher exact test.
ALT  alanine aminotransferase; AST  aspartate aminotransferase; CK  creatine kinase;
ACE major adverse cardiac events; TLR  target lesion revascularization; TVR  target vessel
evascularization.10
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Figure 5 Relationship Between LDL-C
and Percent Change in Plaque Volume
(A) Relationship between the follow-up low-density lipoprotein (LDL)-C level and
percent change in plaque volume during 8- to 12-month follow-up. (B) Relation-
ship between the baseline LDL-C level and percent change in plaque volume dur-
ing 8- to 12-month follow-up. (C) Relationship between percent change in LDL-C
and percent change in plaque volume during 8- to 12-month follow-up. There
was no or slightly week correlation in these relationships.nd relatively low echoic, with a uniform texture having
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urface.
onclusions
ntensive statin therapy with 4 mg/day of pitavastatin or 20
g/day of atorvastatin in patients with ACS resulted in
ignificant regression of atheroma burden with negative
essel remodeling in a large-scale, multicenter trial using a
entral IVUS core laboratory in which the noninferiority of
itavastatin to atorvastatin was proved.
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